Haemonetics Co. (NYSE:HAE) Shares Acquired by Westfield Capital Management Co. LP

Westfield Capital Management Co. LP lifted its position in shares of Haemonetics Co. (NYSE:HAE) by 27.2% during the fourth quarter, Holdings Channel.com reports. The firm owned 712,061 shares of the medical instruments supplier’s stock after acquiring an additional 152,098 shares during the period. Westfield Capital Management Co. LP’s holdings in Haemonetics were worth $60,888,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors have also recently added to or reduced their stakes in HAE. Principal Financial Group Inc. grew its stake in Haemonetics by 0.4% in the 3rd quarter. Principal Financial Group Inc. now owns 199,360 shares of the medical instruments supplier’s stock valued at $17,859,000 after acquiring an additional 844 shares during the period. California Public Employees Retirement System grew its stake in Haemonetics by 53.5% in the 3rd quarter. California Public Employees Retirement System now owns 167,782 shares of the medical instruments supplier’s stock valued at $15,030,000 after acquiring an additional 58,496 shares during the period. Victory Capital Management Inc. grew its stake in Haemonetics by 50.0% in the 3rd quarter. Victory Capital Management Inc. now owns 357,303 shares of the medical instruments supplier’s stock valued at $32,007,000 after acquiring an additional 119,072 shares during the period. Los Angeles Capital Management LLC grew its stake in Haemonetics by 1.1% in the 3rd quarter. Los Angeles Capital Management LLC now owns 53,058 shares of the medical instruments supplier’s stock valued at $4,753,000 after acquiring an additional 586 shares during the period. Finally, Versor Investments LP lifted its holdings in Haemonetics by 84.1% in the 3rd quarter. Versor Investments LP now owns 7,965 shares of the medical instruments supplier’s stock valued at $714,000 after purchasing an additional 3,639 shares in the last quarter. Institutional investors and hedge funds own 99.67% of the company’s stock.

Wall Street Analyst Weigh In

A number of brokerages have weighed in on HAE. Needham & Company LLC restated a “hold” rating on shares of Haemonetics in a report on Friday, May 10th. Barrington Research raised their price objective on Haemonetics from $105.00 to $107.00 and gave the company an “outperform” rating in a report on Friday, May 10th. TheStreet lowered Haemonetics from a “b-” rating to a “c+” rating in a report on Thursday, February 29th. JMP Securities raised their price objective on Haemonetics from $115.00 to $125.00 and gave the company a “market outperform” rating in a report on Friday, May 10th. Finally, StockNews.com lowered Haemonetics from a “buy” rating to a “hold” rating in a report on Friday, March 22nd. Three research analysts have rated the stock with a hold rating and two have assigned a buy rating to the company’s stock. Based on data from MarketBeat, Haemonetics has an average rating of “Hold” and a consensus target price of $108.67.

Haemonetics Trading Down 0.3 %

Shares of NYSE HAE traded down $0.30 during trading on Friday, hitting $88.34. 644,754 shares of the company were exchanged, compared to its average volume of 649,835. Haemonetics Co. has a 12-month low of $70.74 and a 12-month high of $97.97. The company has a debt-to-equity ratio of 0.83, a quick ratio of 1.50 and a current ratio of 2.56. The company has a fifty day moving average price of $87.78 and a 200-day moving average price of $83.42. The firm has a market capitalization of $4.49 billion, a PE ratio of 38.58, a P/E/G ratio of 1.61 and a beta of 0.34.

Haemonetics (NYSE:HAE) last posted its quarterly earnings results on Thursday, May 9th. The medical instruments supplier reported $0.90 EPS for the quarter, topping the consensus estimate of $0.88 by $0.02. Haemonetics had a return on equity of 22.25% and a net margin of 8.98%. The business had revenue of $343.00 million for the quarter, compared to analyst estimates of $329.53 million. During the same quarter in the previous year, the firm earned $0.77 EPS. The company’s quarterly revenue was up 12.7% compared to the same quarter last year. As a group, equities research analysts expect that Haemonetics Co. will post 4.6 EPS for the current year.

Insider Transactions at Haemonetics

In related news, insider Stewart W. Strong sold 686 shares of the business’s stock in a transaction dated Monday, May 20th. The shares were sold at an average price of $95.11, for a total value of $65,245.46. Following the sale, the insider now directly owns 18,196 shares in the company, valued at approximately $1,730,621.56. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. In related news, EVP Anila Lingamneni sold 2,305 shares of the business’s stock in a transaction dated Monday, May 6th. The shares were sold at an average price of $95.00, for a total value of $218,975.00. Following the sale, the executive vice president now directly owns 12,295 shares in the company, valued at approximately $1,168,025. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, insider Stewart W. Strong sold 686 shares of the business’s stock in a transaction dated Monday, May 20th. The shares were sold at an average price of $95.11, for a total transaction of $65,245.46. Following the completion of the sale, the insider now owns 18,196 shares in the company, valued at $1,730,621.56. The disclosure for this sale can be found here. Insiders have sold a total of 5,533 shares of company stock worth $526,404 in the last quarter. Company insiders own 1.79% of the company’s stock.

Haemonetics Company Profile

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app.